The following drug information is obtained from various newswires, published medical journal articles, and medical conference presentations.


Approval Status:

Approved December 1997

Specific Treatments:

rejection of kidney transplants

Therapeutic Areas

Find Related Trials for The Following Conditions

General Information

Hoffman-La Roche's new monoclonal antibody drug, Zenapax (daclizumab), has been approved to prevent rejection of kidney transplants. The drug uses the body's own immune system to prevent the acute rejection that can make kidney transplants fail.

Clinical Results

The FDA said its approval was based on two clinical trials that showed Zenapax significantly reduced acute rejections in patients who got the drug along with the standard three-drug cocktail of immunosuppressant drugs. Patients on Zenapax had 37 to 40% fewer rejections episodes than those given an inert placebo.